Orexigen, Amylin gain on diabetes studies

Orexigen Therapeutics and Amylin Pharmaceuticals managed to break from the market's downward trend early Monday, with shares of the two biotechs gaining on positive studies unveiled over the weekend at a scientific meeting of the American Diabetes Association.